Published in Clin Infect Dis on September 07, 2000
Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia | NCT01966796
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003) 9.54
Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev (2004) 7.51
Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev (2002) 7.42
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax (2001) 4.68
Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med (2007) 3.69
Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med (2008) 3.44
The SAGE Guideline Model: achievements and overview. J Am Med Inform Assoc (2007) 3.22
Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One (2008) 2.39
Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med (2012) 2.38
Impact of clinical practice guidelines on the clinical microbiology laboratory. J Clin Microbiol (2004) 2.25
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18
Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol (2011) 1.78
Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis (2003) 1.74
Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care (2006) 1.70
Ameba-associated microorganisms and diagnosis of nosocomial pneumonia. Emerg Infect Dis (2006) 1.66
Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis (2005) 1.64
Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J (2004) 1.55
Mimivirus in pneumonia patients. Emerg Infect Dis (2005) 1.55
The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax (2006) 1.53
Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis (2006) 1.52
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care? Health Serv Res (2007) 1.49
History and development of evidence-based medicine. World J Surg (2005) 1.48
Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med (2002) 1.47
Prophylactic endotracheal intubation in critically ill patients undergoing endoscopy for upper GI hemorrhage. Gastrointest Endosc (2009) 1.46
Bacteriological and clinical profile of Community acquired pneumonia in hospitalized patients. Lung India (2010) 1.42
Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis (2002) 1.41
Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Qual Saf Health Care (2007) 1.36
The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health (2011) 1.35
Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax (2006) 1.35
Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax (2006) 1.33
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother (2003) 1.32
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother (2002) 1.30
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother (2004) 1.30
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis (2003) 1.28
An unusual cause of chronic cough. Foreign body aspiration. J Gen Intern Med (2006) 1.27
Long-term survival and quality of life after transfusion-associated pulmonary edema in critically ill medical patients. Chest (2009) 1.18
Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax (2005) 1.17
Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest (2009) 1.17
Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis (2003) 1.15
Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother (2007) 1.14
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med (2009) 1.13
The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care (2005) 1.09
Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother (2003) 1.08
Physician awareness and self-reported use of local and national guidelines for community-acquired pneumonia. J Gen Intern Med (2003) 1.08
Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis (2006) 1.07
Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums. J Clin Microbiol (2002) 1.05
Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother (2003) 1.04
Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 1.04
Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care. Chest (2004) 1.01
Development and evaluation of a novel multiplex PCR technology for molecular differential detection of bacterial respiratory disease pathogens. J Clin Microbiol (2008) 1.01
Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother (2004) 1.01
Point-of-care testing in microbiology: the advantages and disadvantages of immunochromatographic test strips. Dtsch Arztebl Int (2009) 1.00
What Is the Clinical Impact of Macrolide Resistance? Curr Infect Dis Rep (2004) 1.00
CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. Proc Natl Acad Sci U S A (2012) 0.99
Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother (2006) 0.98
Capture-recapture estimation of underreporting of legionellosis cases to the National Legionellosis Register: Italy 2002. Epidemiol Infect (2006) 0.98
Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect Immun (2007) 0.96
Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis (2005) 0.96
Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis (2015) 0.95
Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae. Antimicrob Agents Chemother (2011) 0.95
Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med (2006) 0.94
PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review & meta-analysis. Indian J Med Res (2011) 0.94
Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis (2006) 0.93
Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis (2011) 0.92
Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care (2012) 0.92
Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci (2006) 0.91
Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care (2011) 0.91
Economic burden and epidemiology of pneumonia in Korean adults aged over 50 years. J Korean Med Sci (2013) 0.89
Usefulness of Gram stain for diagnosis of lower respiratory tract infection or urinary tract infection and as an aid in guiding treatment. Eur J Clin Microbiol Infect Dis (2003) 0.89
Email recruitment to use web decision support tools for pneumonia. Proc AMIA Symp (2002) 0.89
Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir Res (2005) 0.89
Pneumonia severity index in the immunocompromised. Can Respir J (2006) 0.88
Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis (2005) 0.88
Sequence patterns in the resolution of clinical instabilities in community-acquired pneumonia and association with outcomes. J Gen Intern Med (2013) 0.88
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother (2003) 0.88
Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis (2006) 0.88
Association of hypoglycemia with mortality for subjects hospitalized with pneumonia. Am J Med Sci (2010) 0.87
Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study. Clin Ther (2008) 0.87
Using the electronic medical record to identify community-acquired pneumonia: toward a replicable automated strategy. PLoS One (2013) 0.87
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care (2009) 0.86
Development and validation of a short questionnaire in community acquired pneumonia. Thorax (2004) 0.86
Antimicrobial resistance in Streptococcus pneumoniae, Taiwan. Emerg Infect Dis (2002) 0.86
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. J Emerg Med (2007) 0.86
Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med (2016) 0.86
Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. Clin Vaccine Immunol (2006) 0.85
Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? World J Gastrointest Pharmacol Ther (2011) 0.85
The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm Med (2005) 0.84
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis (2004) 0.84
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother (2003) 0.84
Limited effect of patient and disease characteristics on compliance with hospital antimicrobial guidelines. Eur J Clin Pharmacol (2006) 0.84
Algorithm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing. J Clin Microbiol (2003) 0.84
Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study. Crit Care (2010) 0.84
Burr hole evacuation for infratentorial subdural empyema. World J Clin Cases (2013) 0.83
Is antibiotic resistance a problem? A practical guide for hospital clinicians. Postgrad Med J (2005) 0.83
Patterns of antimicrobial use for respiratory tract infections in older residents of long-term care facilities. J Am Geriatr Soc (2011) 0.83
Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Crit Care (2011) 0.83
Processes of care and outcomes for community-acquired pneumonia. Am J Med (2011) 0.83
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J (1999) 5.88
Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA (1997) 5.85
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med (1991) 5.85
Urease. The primary cause of infection-induced urinary stones. Invest Urol (1976) 4.72
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis (1998) 4.55
Professional courtesy--current practices and attitudes. N Engl J Med (1993) 4.52
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Haemophilus influenzae infections in adults: characterization of strains by serotypes, biotypes, and beta-lactamase production. J Infect Dis (1981) 3.45
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis (1999) 3.15
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA (1998) 3.03
Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA (1997) 2.91
Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis (1993) 2.84
Disk diffusion susceptibility testing of Nocardia species. J Infect Dis (1977) 2.77
Severe diabetes associated with protease inhibitor therapy. Ann Intern Med (1997) 2.71
Resting electrocardiograms as baseline tests: impact on the management of elderly patients. Am J Med (1991) 2.53
An evaluation of machine-learning methods for predicting pneumonia mortality. Artif Intell Med (1997) 2.49
Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics (2001) 2.41
Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J Infect Dis (1994) 2.37
Utilization of health care services among subgroups of urban homeless and housed poor. J Health Polit Policy Law (1999) 2.36
Role of the Escherichia coli O157:H7 O side chain in adherence and analysis of an rfb locus. Infect Immun (1996) 2.36
Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis (1986) 2.34
Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics (1999) 2.34
Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med (1996) 2.29
In vitro lymphocyte response to Treponema refringens im human syphilis. Infect Immun (1974) 2.27
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother (2000) 2.22
Pneumonia and acute febrile tracheobronchitis due to haemophilus influenzae. Ann Intern Med (1983) 2.20
Lymphocyte transformation in syphilis: an in vitro correlate of immune suppression in vivo? Infect Immun (1975) 2.17
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Clinical manifestations of halophilic non-cholera Vibrio infections. Lancet (1974) 2.14
Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus ("Streptococcus milleri group") are of different clinical importance and are not equally associated with abscess. Clin Infect Dis (2001) 2.13
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med (1999) 2.09
Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916. Infect Immun (1990) 2.06
Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis (1990) 2.06
Antimicrobial use in defined populations of infants and young children. Arch Pediatr Adolesc Med (2000) 2.01
Prevention of infected urinary stones by urease inhibition. Invest Urol (1973) 2.00
Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis (1996) 1.98
Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship. Clin Infect Dis (2012) 1.97
Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis (2000) 1.89
Correlation of increased metabolic activity, resistance to infection, enhanced phagocytosis, and inhibition of bacterial growth by macrophages from Listeria- and BCG-infected mice. Infect Immun (1972) 1.85
Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis (2002) 1.84
Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med (1992) 1.81
Inhibition of the antibacterial activity of gentamicin by urine. J Infect Dis (1976) 1.78
Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis (1995) 1.78
The diagnostic value of sputum culture in acute pneumonia. JAMA (1975) 1.75
An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med (1994) 1.73
Community-acquired pneumonia: can it be defined with claims data? Am J Med Qual (1997) 1.71
Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis (1985) 1.71
Bacterial spinal epidural abscess. Review of 43 cases and literature survey. Medicine (Baltimore) (1992) 1.71
Role of urease in pyelonephritis resulting from urinary tract infection with Proteus. J Infect Dis (1975) 1.71
Detection of nonspecific resistance to Listeria monocytogenes in rabbits infected with Treponema pallidum. Infect Immun (1974) 1.69
Hemophilus influenzae pneumonia in adults. Am J Med (1978) 1.69
Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis (1980) 1.68
Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J Infect Dis (1977) 1.65
Incidence of respiratory pathogens in persons hospitalized with pneumonia in two provinces in Thailand. Epidemiol Infect (2010) 1.65
Opsonizing and bactericidal effects of normal human serum on nontypable Haemophilus influenzae. Infect Immun (1983) 1.62
Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement. Clin Orthop Relat Res (1991) 1.59
Polymicrobial bacteremia: clinical and microbiologic patterns. Rev Infect Dis (1989) 1.59
Temporal trends in outcomes of older patients with pneumonia. Arch Intern Med (2000) 1.58
Inhibition of bacterial urease. Invest Urol (1973) 1.57
In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin. Antimicrob Agents Chemother (1995) 1.56
Osteomyelitis associated with pressure sores. Arch Intern Med (1994) 1.56
Current attitudes regarding use of antimicrobial agents: results from physician's and parents' focus group discussions. Clin Pediatr (Phila) (1998) 1.55
Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med (1997) 1.54
Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest (1996) 1.49
Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med (1992) 1.46
Testing of Streptococcus pneumoniae for resistance to penicillin. J Clin Microbiol (1993) 1.46
Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia. Med Care (1998) 1.46
Amebiasis presenting as pleuropulmonary disease. West J Med (1985) 1.45
The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med (1997) 1.44
Antibiotic-induced suprainfection. J Infect Dis (1969) 1.42
Q fever. Arch Intern Med (1988) 1.39
Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med (1996) 1.38
Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis. J Immunol (1986) 1.38
Phagocytosis and killing of Brucella by human polymorphonuclear leukocytes. J Infect Dis (1985) 1.35
Infections due to Staphylococcus aureus. Medicine (Baltimore) (1977) 1.34
Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis (2000) 1.33
Interaction between acetohydroxamic acid and 12 antibiotics against 14 gram-negative pathogenic bacteria. Antimicrob Agents Chemother (1974) 1.32
Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis (1992) 1.32
Vertebral osteomyelitis. Still a diagnostic pitfall. Arch Intern Med (1976) 1.29
Resistance of Vibrio vulnificus to serum bactericidal and opsonizing factors: relation to virulence in suckling mice and humans. J Infect Dis (1984) 1.27
Hypoglycemia as a manifestation of sepsis. Am J Med (1980) 1.26
Spinal epidural abscess. Med Clin North Am (1985) 1.26
Edouard Seguin and the social power of thermometry. N Engl J Med (1987) 1.26
Suppression of phagocytosis and chemotaxis by cell wall components of Staphylococcus aureus. J Immunol (1981) 1.25
Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Clin Infect Dis (1996) 1.24
Immunoglobulin A from bronchopulmonary secretions blocks bactericidal and opsonizing effects of antibody to nontypable Haemophilus influenzae. Infect Immun (1984) 1.24
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA (1997) 1.23
Antibiotic susceptibilities of genetically characterized Streptococcus milleri group strains. Antimicrob Agents Chemother (2001) 1.23
Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med (1996) 1.22
Aberrant secondary antibody responses to sheep erythrocytes in rabbits with experimental syphilis. Infect Immun (1979) 1.22
Permanent carriers of nontyphosa salmonellae. Arch Intern Med (1973) 1.22
Wound zygomycosis (mucormycosis) in otherwise healthy adults. Am J Med (1988) 1.22
Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. J Gen Intern Med (2001) 1.22
A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis (1993) 1.21
Effects of BCG infection on the susceptibility of mouse macrophages to endotoxin. Infect Immun (1979) 1.21